Charles Craddock, CBE, FRCP(UK), FRCPath, DPhil, University of Birmingham, Birmingham, UK, discusses the value of achieving complete remission (CR) after allogeneic hematopoietic stem cell transplantation (alloHSCT) and the impact of pre-transplant measurable residual disease (MRD) positivity on alloHSCT decisions in patients with high-risk acute myeloid leukemia (AML). It has been shown that alloHSCT can be a curative strategy for fit patients who do not achieve CR after two courses of induction chemotherapy. However, two prospective studies have demonstrated that patients with pre-transplant MRD positivity have an increased risk of relapse following alloHSCT, which raises the question of whether these patients should undergo transplantation. Prof. Craddock explains that a recent study has shown that despite this increased risk, a significant number of patients who achieve morphological remission with pre-transplant MRD positivity can still achieve long-term disease-free survival (DFS). For this patient population with pre-transplant MRD positivity, it is important to optimize conditioning regimens. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.

свернуть